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Material and Methods: The study included 150 postmenopausal breast
cancer patients with detectable levels of steroid receptors (ER+PR+) that
should indicate hormone dependent disease. IL-8 and MMP-9 levels were
determined by ELISA in primary tumor tissue lysates.
Results: There was a strong positive correlation between IL-8 and MMP-9
expression (Spearman rank order test, p < 0.001). Furthermore, MMP-9
expression was signiﬁcantly higher in patients with higher levels of IL-8
according to median IL-8 level (M = 28.42 pg/mg) and IL-8 expression was
signiﬁcantly higher in patients with higher levels of MMP-9 (M = 1.87 ng/mg,
Mann–Whitney rank sum test, p = 0.05 and p = 0.008, respectively). There was
a signiﬁcant negative correlation between ER and IL-8, as well as between
PR and IL-8 expression (Spearman rank order test, p = 0.02 and 0.006,
respectively). There was no statistically signiﬁcant correlation between ER and
MMP-9 expression, neither between PR and MMP-9.
Conclusions: Positive feedback loop between IL-8 and MMP-9 might be
mechanism of promotion of angiogenesis and progression of hormone
dependent breast cancer.
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Background: Apoptosis is regulated by several gene products including Bcl-2,
which has been known to be anti-apoptotic property. Additionally, telomerase,
a ribonucleoprotein that synthesizes telomeres, has been identiﬁed in various
human neoplasms and its potential roles should be clariﬁed. In the present
study, we investigated the apoptotic effect of Bcl-2 and telomerase activity in
the surgical specimens of human brain tumors.
Material and Methods: A total of 76 cases of surgically resected brain
tumors were included in this study. Telomerase activity was examined by the
telomeric repeat ampliﬁcation protocol assay, and Bcl-2 was characterized by
the Western blot analysis. Apoptosis of the specimens was detected by DNA
fragmentation analysis.
Results: Telomerase activity was detected in 65.8% (50/76) of the brain
tumors, which induced apoptosis in 20.0% (10/50). Bcl-2 was also expressed
in 23.7% (18/76) of the brain tumors, which induced apoptosis in 11.1%
(2/18). In 14 cases with Bcl-2 expression and negative telomerase activity,
apoptosis was detected in 21.4% (3/14). However, apoptosis was not induced
in all 4 cases with Bcl-2 expression and positive telomerase activity. These
results suggested that apoptosis was enhanced in the brain tumors with Bcl-2
expression and negative telomerase activity (p < 0.05). In the 24 cases without
Bcl-2 expression and telomerase activity, apoptosis was found in 25% (6/24).
Apoptosis was induced in 23.4% (8/34) of brain tumors, which Bcl-2 was
not expressed and telomerase activity was positive. Their difference was not
signiﬁcant statistically.
Conclusions: Our results suggest that apoptosis of the human brain tumors
with Bcl-2 expression may be inﬂuenced by telomerase activity, however,
telomerase activity may not affect on apoptosis of the human brain tumors
without Bcl-2 expression. These indicate that telomerase activity may have a
dependent effect on apoptosis of the human brain tumors.
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Introduction: Novel platinum(II)–iodido complexes of general formula
[PtI2(L
1−3)], (complexes C1−C3, ligands L1−L3): where L1−3 are isobutyl,
n-pentyl and isopentyl esters of (S,S)-propylenediamine-N,N′-di-2-(3-cyclo-
hexyl)propanoic acid have been synthesized and characterized by elemental
analysis, UV/Vis, IR, NMR spectroscopy and mass spectrometry, in order to
investigate their biological activity and to elucidate the mechanism of action.
All studies were performed in comparison to cisplatin.
Material and Method: The cytotoxic activity of the complexes C1−C3 and
ligands L1−L3 was investigated by MTT assay for 48 h of continual action on
four tumor cell lines HeLa, LS-174, MDA-MB-231; one transformed endothelial
cell line EA.hy 926; and one normal MRC-5 cell line. Quantitative analysis of
cell cycle phase distribution was performed by ﬂow-cytometric analysis of the
DNA content in ﬁxed HeLa cells, after staining with propidium iodide. Analyses
of the mode of cell death were performed using ﬂow cytometry by Annexin-V-
FITC assay, and ﬂuorescence microscopy.
Results and Discussion: Complexes C1−C3 exhibited activity comparable
to cisplatin, with the highest potential in HeLa, LS-174 and EA.hy 926
cells. Precursor ligands (L1−L3) showed approximately two- to four-
times less activity comparing to the corresponding complexes irrelevant
to the target cell line, with the highest activity observed in EA.hy 926.
MRC-5 and A549 cells were the least sensitive to the action of
complexes and ligands. C1−C3 induced apoptotic changes characterized
by externalization of phosphatidylserine, generation of considerable sub-
G1 peak and some apoptotic morphological alteration. Only C1 showed
higher potential for apoptosis induction in comparison to the precursor L1
and cisplatin.
Conclusion: Structure-activity comparison in this study revealed that co-
ordination of (S,S)-propylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid
esters to platinum(II) metal center resulted in increased cytotoxicity of
complexes, comparing to precursor ligands. Cytotoxic activity of C1−C3, was
comparable or higher to those observed for cisplatin. Analyses of the mode
of cell death by ﬂow cytometry and ﬂuorescence microscopy, suggested
different mechanism of action of novel iodido-platinum complexes compared
to cisplatin. Altogether novel iodide-platinum complexes showed promising
biological activity and their potential in cisplatin resistant cell lines should be
further investigated.
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Background: RANK is a key pathway of mammary gland differentiation and
mediates progesterone induced mammary tumorigenesis in mice. However,
the therapeutic impact of targeting RANK signaling in established tumors is
unknown.
Materials and Methods: Expression proﬁle of RANK and RANKL was
characterized by quantitative PCR and immunohistochemistry in MMTV-neu
and MMTV-PyMT normal tissues and tumors. For primary cultures, tumors
were plated in 3D matrigel cultures and RANK signaling was stimulated with
RANKL. For in-vivo assays 3D colonies where dispersed into single cells and
injected in mammary glands (tumor growth assays) or tail vein (metastasis
assays) of immunodeﬁcient mice.
Results: RANK is highly expressed in tumors of two widely used models
of spontaneous mammary tumorigenesis: MMTV-neu and MMTV-PyMT.
Stimulation of RANK signaling by RANKL in cells derived from MMTV-neu and
MMTV-PyMT carcinomas promotes cell proliferation, survival and increased
tumor growth rate. In addition, RANKL treatment results in increased invasion
of tumor cells and increased metastasis formation ability.
Conclusions: RANK signaling plays an important role in mammary tumor
progression and targeting RANK may be beneﬁcial for breast cancer therapy.
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Introduction: Voltage-gated Na+ channels (VGSCs) are heteromeric proteins
composed of pore-forming alpha subunits and smaller beta subunits. The beta
subunits are channel modulators and are also cell adhesion molecules (CAMs).
Beta1, encoded by SCN1B, is best characterized in the central nervous system
(CNS), where it regulates electrical excitability, neurite outgrowth and migration
during development. Beta1 is also expressed in breast cancer cell lines, where
it regulates adhesion and migration in vitro. Here, we show that beta1 plays a
functional role as a CAM in regulating tumour growth and metastasis.
Materials and Methods: We studied beta1 expression using Oncomine and
immunohistochemical analysis of patient tissue specimens. We investigated
the effects of beta1 on tumour growth and metastasis by orthotopic
injection of MDA-MB-231 cells into mice, followed bioluminescent imaging,
immunohistochemistry and confocal microscopy. The effect of beta1 on
process outgrowth was assessed by immunocytochemical analysis of breast
cancer cells grown on ﬁbroblast monolayers.
Results: SCN1B mRNA and beta1 protein were up-regulated in breast
tumours, compared with normal tissue. Over-expression of beta1 in MDA-
MB-231 cells increased tumor growth and metastasis in a xenograft model
of breast cancer. Beta1 overexpression also increased VEGF secretion and
vascularisation, but reduced apoptosis. Beta1 potentiated outgrowth of neurite-
like processes from breast cancer cells cultured with ﬁbroblasts. Process
outgrowth in breast cancer cells speciﬁcally required the extracellular adhesion
domain of beta1. Beta1-mediated process outgrowth also required Na+ current
and fyn kinase activity.
Conclusions: Beta1-mediated process outgrowth in breast cancer cells
recapitulates the mechanism by which beta1 regulates neurite outgrowth
in CNS neurons. We conclude that when present in breast tumors, beta1
enhances pathological growth and cellular dissemination by recapitulating
